Nektar's safety study is on-going. I guess far behind is a relative term I think ~2 years. If projections on market size are accurate (couple billion) and neither product has a significant distinguishing advantage then I would figure both drugs could do well. However Nektar presents their data in terms of a drug that is intended for chronic use. I almost get the sense that Relistor is intended for acute use in that they seem primarily emphasize time to first spontaneous bowl movement and the chronic use is not emphasized as much. Maybe just my impression.
News 
Market Data 
Discover 
AI
